Herantis Pharma Oyj (HE:HRTIS) — Market Cap & Net Worth
Market Cap & Net Worth: Herantis Pharma Oyj (HRTIS)
Herantis Pharma Oyj (HE:HRTIS) has a market capitalization of $42.45 Million (€36.31 Million) as of October 6, 2026. Listed on the HE stock exchange, this Finland-based company holds position #22536 globally and #111 in its home market, demonstrating a -2.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Herantis Pharma Oyj's stock price €1.37 by its total outstanding shares 26503817 (26.50 Million).
Herantis Pharma Oyj Market Cap History: 2015 to 2026
Herantis Pharma Oyj's market capitalization history from 2015 to 2026. Data shows growth from $34.08 Million to $42.45 Million (2.45% CAGR). Check Herantis Pharma Oyj stock price for real-time trading data and today's change.
Index Memberships
Herantis Pharma Oyj is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Finland EUR PI
FNFIEURPI
|
$1.59 Billion | 2.67% | #10 of 25 |
Weight: Herantis Pharma Oyj's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Herantis Pharma Oyj Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Herantis Pharma Oyj's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see HRTIS operating cash flow for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
3491.73x
Herantis Pharma Oyj's market cap is 3491.73 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $34.08 Million | $1.96K | -$16.05 Million | 17434.44x | N/A |
| 2016 | $88.31 Million | $25.29K | -$4.42 Million | 3491.73x | N/A |
Competitor Companies of HRTIS by Market Capitalization
Companies near Herantis Pharma Oyj in the global market cap rankings as of October 6, 2026. See HRTIS equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to Herantis Pharma Oyj by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $127.62 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #379 globally with a market cap of $73.47 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.76 Billion USD ( AU$85.87 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $127.62 Billion | $503.50 |
| #379 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.47 Billion | $726.47 |
| #455 | CSL Ltd | AU:CSL | $60.76 Billion | AU$176.99 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $203.21 |
Herantis Pharma Oyj Historical Marketcap From 2015 to 2026
Between 2015 and today, Herantis Pharma Oyj's market cap moved from $34.08 Million to $ 42.45 Million, with a yearly change of 2.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €42.45 Million | -32.84% |
| 2025 | €63.21 Million | +34.65% |
| 2024 | €46.94 Million | -3.81% |
| 2023 | €48.80 Million | -4.55% |
| 2022 | €51.13 Million | -31.25% |
| 2021 | €74.37 Million | -42.17% |
| 2020 | €128.59 Million | -46.45% |
| 2019 | €240.14 Million | +40.91% |
| 2018 | €170.42 Million | +2.23% |
| 2017 | €166.70 Million | +88.77% |
| 2016 | €88.31 Million | +159.09% |
| 2015 | €34.08 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 6th, 2026 the market cap of Herantis Pharma Oyj was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $42.45 Million USD |
| MoneyControl | $42.45 Million USD |
| MarketWatch | $42.45 Million USD |
| marketcap.company | $42.45 Million USD |
| Reuters | $42.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Herantis Pharma Oyj
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinic… Read more